Advertisement
Screener

INNOVIVA, INC. (INVA) Increase (Decrease) in Other Noncurrent Liabilities

2.8 / 5 stars · 68/120 Roast Me

INNOVIVA, INC. Increase (Decrease) in Other Noncurrent Liabilities

INNOVIVA, INC. (INVA) reported Increase (Decrease) in Other Noncurrent Liabilities of $0 for the 12-month period ending 2021-12-31, per its 10-K/A filed 2022-03-17.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2022-03-17

  • INNOVIVA, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2020-12-31 was $0.00.
  • INNOVIVA, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2019-12-31 was $0.00.
  • INNOVIVA, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2019-09-30 was -$126.00K.
  • INNOVIVA, INC. increase (decrease) in other noncurrent liabilities for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
  • INNOVIVA, INC. increase (decrease) in other noncurrent liabilities for fiscal 2021 was $0.00.
  • INNOVIVA, INC. increase (decrease) in other noncurrent liabilities for fiscal 2020 was $0.00.
  • INNOVIVA, INC. increase (decrease) in other noncurrent liabilities for fiscal 2019 was -$126.00K, a 3250.00% decline from fiscal 2018.
  • INNOVIVA, INC. increase (decrease) in other noncurrent liabilities for fiscal 2018 was $4.00K, a 75.00% decline from fiscal 2017.
Period endIncrease (Decrease) in Other Noncurrent Liabilities 3 monthIncrease (Decrease) in Other Noncurrent Liabilities 6 monthIncrease (Decrease) in Other Noncurrent Liabilities 9 monthIncrease (Decrease) in Other Noncurrent Liabilities 12 month
2021-12-31$0.00
10-K/A · filed 2022-03-17
2020-12-31$0.00
derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17
$0.00
10-K/A · filed 2022-03-17
2020-09-30$0.00
10-Q · filed 2020-10-28
2019-12-31$0.00
derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17
-$126.00K
derived: sum of 2 quarters · filed 2022-03-17
-$126.00K
derived: sum of 3 quarters · filed 2022-03-17
-$126.00K
10-K/A · filed 2022-03-17
2019-09-30-$126.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28
-$126.00K
derived: sum of 2 quarters · filed 2020-10-28
-$126.00K
10-Q · filed 2020-10-28
-$126.00K
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24
$0.00
10-Q · filed 2019-07-24
$0.00
derived: sum of 3 quarters · filed 2021-02-25
$0.00
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31$0.00
10-Q · filed 2019-05-01
$0.00
derived: sum of 2 quarters · filed 2021-02-25
$0.00
derived: sum of 3 quarters · filed 2021-02-25
$2.00K
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$0.00
derived: sum of 2 quarters · filed 2021-02-25
$2.00K
derived: sum of 3 quarters · filed 2021-02-25
$4.00K
10-K · filed 2021-02-25
2018-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30
$2.00K
derived: sum of 2 quarters · filed 2019-10-30
$4.00K
10-Q · filed 2019-10-30
$7.00K
derived: sum of 4 quarters · filed 2020-02-19
2018-06-30$2.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24
$4.00K
10-Q · filed 2019-07-24
$7.00K
derived: sum of 3 quarters · filed 2020-02-19
$10.00K
derived: sum of 4 quarters · filed 2020-02-19
2018-03-31$2.00K
10-Q · filed 2019-05-01
$5.00K
derived: sum of 2 quarters · filed 2020-02-19
$8.00K
derived: sum of 3 quarters · filed 2020-02-19
$13.00K
derived: sum of 4 quarters · filed 2020-02-19
2017-12-31$3.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19
$6.00K
derived: sum of 2 quarters · filed 2020-02-19
$11.00K
derived: sum of 3 quarters · filed 2020-02-19
$16.00K
10-K · filed 2020-02-19
2017-09-30$3.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31
$8.00K
derived: sum of 2 quarters · filed 2018-10-31
$13.00K
10-Q · filed 2018-10-31
$19.00K
derived: sum of 4 quarters · filed 2019-02-19
2017-06-30$5.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26
$10.00K
10-Q · filed 2018-07-26
$16.00K
derived: sum of 3 quarters · filed 2019-02-19
$96.00K
derived: sum of 4 quarters · filed 2019-02-19
2017-03-31$5.00K
10-Q · filed 2018-05-04
$11.00K
derived: sum of 2 quarters · filed 2019-02-19
$91.00K
derived: sum of 3 quarters · filed 2019-02-19
$15.00K
derived: sum of 4 quarters · filed 2019-02-19
2016-12-31$6.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19
$86.00K
derived: sum of 2 quarters · filed 2019-02-19
$10.00K
derived: sum of 3 quarters · filed 2019-02-19
$8.00K
10-K · filed 2019-02-19
2016-09-30$80.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03
$4.00K
derived: sum of 2 quarters · filed 2017-11-03
$2.00K
10-Q · filed 2017-11-03
$0.00
derived: sum of 4 quarters · filed 2018-02-23
2016-06-30-$76.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08
-$78.00K
10-Q · filed 2017-08-08
-$80.00K
derived: sum of 3 quarters · filed 2018-02-23
-$82.00K
derived: sum of 4 quarters · filed 2018-02-23
2016-03-31-$2.00K
10-Q · filed 2017-05-05
-$4.00K
derived: sum of 2 quarters · filed 2018-02-23
-$6.00K
derived: sum of 3 quarters · filed 2018-02-23
$7.00K
derived: sum of 4 quarters · filed 2018-02-23
2015-12-31-$2.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
-$4.00K
derived: sum of 2 quarters · filed 2018-02-23
$9.00K
derived: sum of 3 quarters · filed 2018-02-23
-$7.00K
10-K · filed 2018-02-23
2015-09-30-$2.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03
$11.00K
derived: sum of 2 quarters · filed 2016-11-03
-$5.00K
10-Q · filed 2016-11-03
2015-06-30$13.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
-$3.00K
10-Q · filed 2016-08-04
2015-03-31-$16.00K
10-Q · filed 2016-05-05
2014-12-31$275.00K
10-K · filed 2017-02-28
2013-12-31-$299.00K
10-K · filed 2016-02-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
OMEROS CORP (OMER)United States$1.456B5.50
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10